Diligence memo · auto-generated · as of July 2, 2026
Vaxess Technologies, Inc.
Vaxess Technologies, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Vaxess Technologies, Inc. operates in Biotechnology, based in WOBURN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vaxess Technologies, Inc. has raised $138M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $57M on 2026-03-04.
Most recent recorded round closed around 2026-03-04.
Valuation (modeled)modeled
Provath models Vaxess Technologies, Inc. at approximately $270M (range $177M–$326M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.40× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era. Within the normal band (140% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 4 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 7.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.